• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vistagen Therapeutics Inc (NQ: VTGN )

    3.535 -0.055 (-1.53%)
    Streaming Delayed Price Updated: 10:14 AM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vistagen Therapeutics Inc

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    7 Cheap Biotech Stocks to Buy Now
    These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
    Via InvestorPlace
    InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    VistaGen Appoints Reid Adler as Chief Legal Officer
    From VistaGen Therapeutics, Inc.
    Via Business Wire
    Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
    Deals, financings, trials and approvals in biotech in China this week. 
    Via Talk Markets
    Recap: VistaGen Therapeutics Q3 Earnings
    VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Earnings Scheduled For February 10, 2022
    Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
    Via Benzinga
    InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses
    Via Investor Brand Network
    VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
    From VistaGen Therapeutics, Inc.
    Via Business Wire
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
    Via Investor Brand Network
    VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
    From VistaGen Therapeutics, Inc.
    Via Business Wire
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference
    Via Investor Brand Network
    Stocks That Hit 52-Week Lows On Monday
    On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers Creative Medical Tech (NASDAQ:CELZ 
    Via Benzinga
    VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
    According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54... 
    Via Benzinga
    InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update
    Via Investor Brand Network
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call
    Via Investor Brand Network
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18
    Via Investor Brand Network
    InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights
    Via Investor Brand Network
    InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update
    Via Investor Brand Network
    VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
    VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and... 
    Via Benzinga
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
    Via Investor Brand Network
    Exposures COVID-19
    InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity
    Via Investor Brand Network
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers MorphoSys (NASDAQ:MOR) stock move... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Gainers Cellect Biotechnology (NASDAQ:APOP 
    Via Benzinga
    Recap: VistaGen Therapeutics Q1 Earnings
    Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the... 
    Via Benzinga
    Looking Into VistaGen Therapeutics's Return On Capital Employed
    In Q4, VistaGen Therapeutics (NASDAQ:VTGN) posted sales of $441.90 thousand. Earnings were up 17.36%, but VistaGen Therapeutics still reported an overall loss of $6.22 million.... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers Dare Bioscience (NASDAQ:DARE) sto... 
    Via Benzinga
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.